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Summary
Background.  —  Remote  ischaemic  preconditioning  (RIPC)  protects  tissues  against  ischaemia-
reperfusion  (I/R)  injury,  a  common  occurrence  in  several  clinical  settings.disease;
Ischaemia-
reperfusion
Aims. —  To  evaluate  whether  RIPC  has  a  beneﬁcial  impact  on  walking  disability  in  arterial
intermittent  claudication.
Methods.  —  A  total  of  20  patients  with  proven  intermittent  claudication  underwent  two  tread-
mill walking  tests  with  a  7-day  interval  in  between;  they  were  randomized  according  to  the  order
in which  they  received  either  RIPC  or  a  control  procedure  before  the  ﬁrst  treadmill  test,  with
Abbreviations: ATP, adenosine triphosphate; bpm, beats per minute; DROP, decrease in oxygen pressure from rest; DROPend, the value
f the DROP index observed at the end of exercise; HR, heart rate; HRmax, maximal heart rate value; I/R, ischaemia-reperfusion; NIRS,
ear infrared spectroscopy; RIPC, remote ischaemic preconditioning; StO2end, haemoglobin oxygen saturation value at the end of exercise;
TPD, standard temperature and pressure, dry; TcPO2, transcutaneous oxygen pressure; VCO2, carbon dioxide production; VCO2end, carbon
ioxide production at the end of exercise; VO2, oxygen consumption; VO2end, oxygen consumption at the end of exercise.
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a  crossover  at  the  second  test.  Patients  received  three  cycles  of  alternating  5-minute  inﬂation
and 5-minute  deﬂation  of  blood-pressure  cuffs  on  both  arms,  with  inﬂation  to  a  pressure  of
200 mmHg  in  the  RIPC  procedure  or  10  mmHg  in  the  control  procedure.  Walking  distances  and
limb oxygenation  data,  assessed  with  transcutaneous  oximetry  and  near  infrared  spectroscopy
measurements,  were  obtained  during  both  RIPC  and  control  procedures  in  all  patients.
Results. —  Similar  exercise  intensities  were  achieved  after  the  control  and  RIPC  procedures.
Walking distances  did  not  signiﬁcantly  differ  after  the  control  and  RIPC  procedures  (204
[141—259] m  vs  215  [162—442]  m,  respectively;  P  =  0.22).  Similarly,  no  difference  was  observed
in terms  of  transcutaneous  oxygen  pressure  change  and  near  infrared  spectroscopy  measure-
ments during  exercise  between  the  two  procedures.
Conclusion.  —  RIPC  did  not  improve  walking  distance  or  limb  ischaemia  variables  in  patients
with peripheral  artery  disease  and  intermittent  claudication.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  capacité  d’un  préconditionnement  ischémique  à  distance  (RIPC)  à  protéger  les
tissus exposés  à  une  ischémie-reperfusion  a  été  démontrée  dans  plusieurs  situations  cliniques.
Objectif. —  Évaluer  l’effet  du  RIPC  dans  l’artériopathie  oblitérante  des  membres  inférieurs  avec
claudication.
Méthodes.  —  Vingt  patients  souffrant  d’une  claudication  des  membres  inférieurs  avérée  ont
réalisé 2  tests  de  marche  sur  tapis  à  7  jours  d’intervalle.  Ils  ont  été  randomisés  pour  recevoir,
soit le  RIPC,  soit  la  procédure  contrôle  lors  du  premier  test  puis  les  procédures  ont  été  inversées
pour le  second  test.  Un  brassard  à  tension  a  été  gonﬂé  aux  deux  bras  en  alternance  selon
une séquence  de  3  inﬂations  de  5  minutes  espacées  de  5  minutes.  Le  brassard  était  gonglé  à
200 mmHg  pour  le  RIPC  et  à  10  mmHg  pour  la  procédure  contrôle.  La  distance  de  marche  et  les
paramètres  d’oxygénation  des  membres  inférieurs  mesurés  par  oxymétrie  transcutanée  et  par
spectroscopie  infra-rouge  ont  été  relevés  chez  tous  les  patients.
Résultats.  — L’intensité  des  efforts  et  les  distances  de  marche  (204  [141—259]  m  dans  le  groupe
contrôle vs  215  [162—442]  m  dans  le  groupe  RIPC  ;  p  =  0,22)  n’ont  pas  été  signiﬁcativement
différentes  entre  les  deux  groupes.  De  même,  il  n’a  pas  été  observé  de  différence  entre  les
deux procédures  concernant  les  paramètres  d’oxygénation  tissulaire.
Conclusion.  — Le  RIPC  n’a  pas  signiﬁcativement  modiﬁé  les  distances  de  marche  et  les
paramètres  d’oxygénation  tissulaire  chez  des  patients  atteints  d’artériopathie  oblitérante  des
membres inférieurs  avec  claudication.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Prolonged  ischaemia  induces  cell  dysfunction  and  death
in  several  cardiovascular  diseases.  The  damage  can  be
ampliﬁed  by  restoring  appropriate  blood  ﬂow.  The  whole
phenomenon  is  named  ischaemia-reperfusion  (I/R)  injury.  In
1986,  Murry  et  al.  ﬁrst  reported  the  concept  of  ischaemic
preconditioning:  a  series  of  short,  non-lethal  periods  of
ischaemia  interspersed  with  reperfusion  periods  that  ren-
dered  a  target  organ  more  resistant  to  a  subsequent
ischaemic  event  [1].  First  assessed  within  one  organ  by
Przyklenk  et  al.  in  1993  [2],  remote  ischaemic  precondition-
ing  (RIPC)  is  a  conditioning  strategy  in  which  an  organ  or
tissue  other  than  the  target  is  exposed  to  brief  periods  of
I/R  for  conditioning  [2—7].  Given  its  advantage  of  avoid-
ing  invasive  procedures,  the  RIPC  technique  using  transient
limb  ischaemia  as  a  stimulus  has  emerged  as  an  attractive
w
e
wtrategy  in  various  clinical  settings  [8,9].  RIPC  was  proven
o  be  able  to  attenuate  I/R  injury  in  patients  undergo-
ng  cardiac  surgery  [10—12],  elective  surgery  for  abdominal
ortic  aneurysm  [13],  elective  percutaneous  coronary  inter-
ention  [14]  and  reperfusion  in  acute  myocardial  infarction
15,16].  RIPC  was  also  found  to  improve  maximal  perfor-
ance  in  highly  trained  swimmers  [17]  and  cyclists  [18].
hile  intensive  exercise  may  represent  a  physiological  form
f  ischaemic  insult  in  healthy  humans,  even  moderate  exer-
ise  (i.e.  walking)  exposes  patients  with  peripheral  artery
isease  and  intermittent  claudication  to  the  risk  of  I/R
njury.  For  this  reason,  the  Protection  de  l’artéritique  par
onditionnement  à  distance  ([PARADIS]:  arterial  protection
ia  remote  conditioning)  study  was  designed  to  determine
hether  RIPC  induced  by  transient  arm  ischaemia  had  a  ben-
ﬁcial  impact  on  the  maximal  walking  distance  in  patients
ith  intermittent  claudication.
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ethods
tudy design
he  PARADIS  study  was  a  prospective,  double-blind,
rossover,  randomized  controlled  trial,  conducted  at  the
niversity  Hospital  in  Angers,  France.  All  participants  pro-
ided  written  informed  consent.  The  study  protocol  was
pproved  by  the  regional  ethics  committee  and  conducted  in
ccordance  with  the  Declaration  of  Helsinki.  The  study  was
egistered  at  ClinicalTrials.gov  (Identiﬁer:  NCT01971879).
tudy criteria
e  screened  patients  aged  ≥  18  years  who  were  consecu-
ively  referred  to  our  laboratory  for  typical  intermittent
ower-limb  claudication.  To  be  eligible,  patients  had  to
xhibit  an  ankle-to-brachial  index  <  0.90  either  in  the  symp-
omatic  leg  or  in  both,  as  well  as  scoring  positive  on  a
readmill  test  performed  in  our  laboratory.  A  positive  test
as  deﬁned  as  the  combination  of  claudication  experienced
uring  the  treadmill  test,  a  walking  distance  <  750  m,  and
 positive  exercise  oximetry  test  that  was  ipsilateral  to
ymptoms.  A  positive  oximetry  test  was  deﬁned  as  a  DROP
ndex  (changes  in  transcutaneous  pressure  in  oxygen  from
est  at  the  leg  minus  changes  at  the  chest  level)  less  than
15  mmHg  [19].
Patients  displaying  the  following  criteria  were  excluded
rom  the  study:  exercise  hypoxaemia,  deﬁned  as  the  loss
f  ≥  4  points  of  saturation  during  the  treadmill  test;  met-
ormin  intake  within  the  previous  seven  days;  and  humeral
ystolic  blood  pressure  at  rest  >  200  mmHg.
andomization and masking
he  randomization  list  was  computer  generated  by  an  inde-
endent  methodologist.  The  randomization  results  were
ealed  in  envelopes  and  assigned  to  the  patients  after
heir  enrolment  into  the  study.  Each  patient  underwent  two
readmill  tests,  separated  by  a  7-day  interval;  each  test  was
erformed  at  the  same  time  of  day.  Patients  were  random-
zed  according  to  the  order  in  which  they  underwent  either
IPC  or  a  control  procedure  before  the  ﬁrst  treadmill  test,
ith  a  crossover  at  the  second  test.
All  study  investigators  and  participants  were  blinded  to
reatment  assignment  for  the  duration  of  the  study.  Only  the
urse  was  informed  of  the  procedure  (RIPC  or  control)  that
ad  to  be  performed  before  the  treadmill  test.  The  physician
upervising  the  treadmill  test  was  not  told  which  procedure
as  performed  prior  the  treadmill  test,  and  the  patients
ere  not  told  which  procedure  offered  a  potential  beneﬁcial
mpact.  Lastly,  patients  were  requested  not  to  pass  on  any
nformation  to  the  physician  supervising  the  treadmill  test.
rocedures
n  both  the  RIPC  and  control  procedures,  patients  received
hree  cycles  of  alternating  5-minute  inﬂation  and  5-minute
eﬂation  of  standard  upper-arm  blood-pressure  cuffs  on
oth  arms.  The  blood-pressure  cuffs  were  inﬂated  to  a  pres-
ure  of  200  mmHg  and  10  mmHg  in  the  RIPC  and  control
b
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rocedures,  respectively.  The  walking  treadmill  test  began
 minutes  after  the  release  of  the  last  series  of  cuff  inﬂation.
readmill test
he  standard  treadmill  test  was  performed  at  a  10◦ slope
nd  speed  of  3.2  km/h  (transition  phase  from  0  to  3.2  km/h
asting  1  minute).  In  the  absence  of  symptoms  or  in
ases  of  non-limiting  symptoms  after  15  minutes  (approxi-
ately  750  m),  the  speed  and  slope  of  the  treadmill  were
rogressively  increased  every  minute.  The  exercise  was  dis-
ontinued  at  the  patient’s  request.  The  maximal  walking
istance  was  then  recorded.  Oxygen  consumption  during  the
readmill  test  (VO2,  in  mL  O2/kg/min  standard  temperature
nd  pressure,  dry  [STPD]),  carbon  dioxide  production  (VCO2,
n  mL  CO2/kg/min  STPD)  and  heart  rate  (HR,  in  beats  per
inute  [bpm])  were  all  measured  and  recorded  continu-
usly.  VO2 and  VCO2 at  the  end  of  exercise  (VO2end  in  mL
2/kg/min  STPD  and  VCO2end  in  mL  CO2/kg/min  STPD)  were
sed  for  the  analysis.  Maximum  HR  during  exercise  (HRmax)
nd  HR  at  both  1  and  2  minutes  post  exercise  were  used  for
he  analysis.  The  maximal  walking  distance  was  the  major
ndpoint  of  the  study.
issue oxygenation
wo  different  tools  were  used  to  detect  limb  exercise-
nduced  regional  blood  ﬂow  impairment:  transcutaneous
xygen  pressure  (TcPO2)  and  near  infrared  spectroscopy
NIRS).
cPO2 exercise proﬁle
he  TcPO2 exercise  proﬁle  is  a  measurement  of  oxygen  par-
ial  pressure  (PO2) taken  from  the  skin  that  also  offers  the
dvantage  of  detecting  and  accounting  for  exercise-induced
hanges  in  the  chest  by  means  of  a  reference-point  chest
lectrode.  The  standard  technique  consists  of  attaching  a
inimum  of  ﬁve  TcPO2 probes,  one  to  each  calf,  one  to
ach  buttock  and  one  to  the  chest,  to  measure  potential
ystemic  changes  (TCM400;  Radiometer,  Copenhagen,  Den-
ark).  The  calibrations  and  procedures  to  be  used  for  the
cPO2 recordings  have  been  extensively  described  elsewhere
19,20].  The  DROP  index  has  been  proven  to  provide  better
ccuracy  in  detecting  proximal  and  distal  ischaemia  than
cPO2 absolute  values  [19,20].  To  measure  the  DROP  index,
e  corrected  the  TcPO2 change  from  rest  on  each  limb  probe
o  align  with  the  corresponding  absolute  change  from  rest
f  the  chest  electrode  TcPO2 at  each  2-second  interval,  sub-
racting  or  adding  the  chest  TcPO2 changes  from  the  results
f  the  TcPO2 changes  at  limb  if  the  chest  TcPO2 increased
r  decreased,  respectively.  Because  of  the  potential  dif-
erences  in  test  duration,  we  used  the  value  of  the  DROP
ndex  observed  at  the  end  of  exercise  (DROPend)  for  our
nalysis.
IRS-measured saturation
issue  oxygenation  in  both  lower  limbs  was  also  measured
y  NIRS  (NIRO-200NX  system;  Hamamatsu  Photonics,  Hama-
atsu  City,  Shizuoka,  Japan).  NIRS  is  a  surface  technique
sed  for  measuring  skin  and  muscle  oxygen  saturation,  which
as  the  advantage  of  being  instantaneous  [21]. NIRS  is  a
ion  475
Table  1  Patient  characteristics.
Age  (years)  63.4  ±  10.8
Height  (cm)  170  ±  5
Weight  (kg)  81  ±  17
Body  mass  index  (kg/m2)  27.7  ±  5.0
Men  17  (85)
Cardiovascular  risk  factor
Hypertension  16  (80)
Diabetes  mellitus 4  (20)
Hypercholesterolaemia  or
cholesterol-lowering  drugs
20  (100)
Family  history  of  CAD  2  (10)
Current  smoker  8  (40)
Cardiovascular  history
Myocardial  infarction  2  (10)
Angina  pectoris  3  (15)
Percutaneous  coronary  intervention  2  (10)
Coronary  artery  bypass  2  (10)
Lower-limb  stenting  6  (30)
Lower-limb  bypass  8  (40)
Stroke  1  (5)
Carotid  stenosis 5  (25)
Medication
Aspirin  7  (35)
Clopidogrel  14  (70)
Prasugrel  or  ticagrelor 1  (5)
Oral  anticoagulant 0  (0)
Beta-blocker  5  (25)
Cholesterol-lowering  drug 18  (90)
Angiotensin-converting  enzyme 9  (45)
Angiotensin  receptor  blocker 6  (30)
Diuretic  8  (30)
Calcium  antagonists 6  (30)
Ivabradine  1  (5)
Nitrate  0  (0)
Antidiabetic  drug  3  (15)
Corticosteroid  0  (0)
Non-steroidal  anti-inﬂammatory
drug
0 (0)
Peripheral  artery  disease
Self-reported  maximal  walking
distance  (m)
225  [150—300]
PAD  evolution  (years)  4.5  ±  6.9
Ankle-to-brachial  pressure  index  0.64  ±  0.16
Data are expressed as mean ± standard deviation, number (%)
or median (25th—75th percentile).
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promising  tool  for  detecting  ischaemia  in  peripheral  artery
disease  [22].  The  principles  of  NIRS  measurement  have  been
described  elsewhere  [22].  Brieﬂy,  two  NIRS  probes  were
placed  on  the  gastrocnemius  to  project  near-infrared  light
through  the  biological  tissue.  The  levels  of  oxyhaemoglobin,
deoxyhaemoglobin  and  haemoglobin  oxygen  saturation  were
then  recorded  every  second  during  rest,  exercise  and  recov-
ery.  The  absolute  haemoglobin  oxygen  saturation  value  at
the  end  of  exercise  (StO2end)  was  used  for  the  analysis.
Blood lactates
Two  venous  blood  samples  of  3  mL  were  collected  in  vac-
uum  containers  in  a  sodium  ﬂuoride  solution.  These  samples
were  taken  just  before  the  start  of  the  treadmill  test  and
2  minutes  after  the  end.  The  samples  were  placed  on  ice  and
transported  to  the  laboratory  within  15  minutes  of  collec-
tion.  Serum  lactate  concentrations  were  measured  by  means
of  a  routine  automated  assay  (ARCHITECT  c16000;  Abbott
Diagnostics,  Lake  Forest,  IL,  USA).
Statistical analysis
At  the  time  of  designing  the  PARADIS  study,  no  data  existed
concerning  RIPC  use  in  peripheral  artery  disease.  Conducting
RIPC  before  an  incremental  bicycle  exercise  test  was  found
to  improve  maximal  oxygen  consumption  and  power  output
in  15  healthy,  well-trained  cyclists  [18].  Similarly,  RIPC  has
been  shown  to  improve  maximal  performance  in  18  highly
trained  swimmers  [17].  We  therefore  decided  arbitrarily  to
include  20  patients.
All  statistical  tests  were  conducted  by  means  of  a  com-
mercially  available  statistical  programme  (SPSS15;  SPSS,
Inc.,  Chicago,  IL,  USA).  The  data  are  expressed  as  means  ±
standard  deviations  or  medians  (25th—75th  percentiles),
unless  stated  otherwise.  Shapiro-Wilk  and  Kolmogorov-
Smirnov  tests  indicated  a  normal  (Gaussian)  distribution  of
the  data,  except  for  the  walking  distance  during  the  tread-
mill  test.  We  therefore  proceeded  with  a  paired  two-tailed
Student’s  t  test  to  assess  differences  in  oxygen  consumption,
carbon  dioxide  production,  DROPend,  StO2end,  heart  rate
and  lactate  concentration  between  the  two  groups,  along
with  a  Wilcoxon  test  for  the  walking  distance.  A  two-tailed
P  <  0.05  was  set  to  indicate  statistical  signiﬁcance.
Results
The  study  ﬂowchart  is  shown  in  Fig.  1.  Of  the  patients  sched-
uled  for  a  walking  test  between  November  2012  and  April
2013,  30  were  screened  for  eligibility,  with  20  recruited  and
randomly  allocated  to  the  different  procedures.  Walking  dis-
tances  and  tissue  oxygenation  data  were  obtained  during
both  RIPC  and  control  procedures  for  all  patients.
The  baseline  characteristics  of  the  patients  are  shown
in  Table  1.  Major  cardiovascular  risk  factors  were  common
in  the  study  population,  and  most  patients  were  receiving
cholesterol-lowering  medication,  antihypertensive  therapy
and  antiplatelet  treatment.  Three  patients  (15%)  had  a
history  of  myocardial  infarction  or  stroke.  The  median  self-
reported  claudication  distance  was  225  (150—300)  m  and
T
A
iCAD: coronary artery disease; PAD: peripheral artery disease.
he  mean  ±  standard  deviation  ankle-to-brachial  index  was
.64  ±  0.16.
Two  patients  had  a walking  distance  >  750  m,  as  measured
uring  the  control  procedure,  yet  were  still  included  in  the
nalysis  as  they  only  achieved  a  walking  distance  <  750  m  on
he  treadmill  test  at  the  time  of  recruitment.readmill test data
ll  results  are  presented  in  Table  2.  Similar  exercise
ntensities  were  achieved  after  both  the  control  and
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digure 1. Study ﬂowchart. RIPC: remote ischaemic preconditioniIPC  procedures.  VO2end  was  14.6  ±  0.8  mL/kg/min  STPD
fter  the  control  procedure  and  15.2  ±  0.7  mL/kg/min  STPD
fter  RIPC  (P  =  0.25).  Similarly,  HRmax  values  did  not
iffer  signiﬁcantly  between  post-control  and  post-RIPC
m
P
i
Table  2 Treadmill  test  data.
Control  
Walking  distance  (m) 204  [141—
DROPend  (mmHg)  —15.6  ±  9.
StO2end  (%) 37.6  ±  3.2  
VO2end  indexed  (mL/kg/min  STPD)  14.6  ±  0.8  
VCO2end  indexed  (mL/kg/min  STPD)  13.6  ±  1.0  
HRmax  (bpm)  113  ±  18  
1-minute  HR  (bpm)  102  ±  4  
2-minute  HR  (bpm)  93  ±  5  
Pretest  lactate  (mmol/L)  1.16  ±  0.07
End  of  exercise  lactate  (mmol/L)  3.36  ±  0.37
Data are expressed as median (25th—75th percentile) or mean ± stand
bpm: beats per minute; DROPend: mean change in oxygen pressure fr
heart rate value, recorded 1 and 2 minutes after the end of exercise; S
temperature and pressure, dry; VCO2end: carbon dioxide production a
exercise.easurements  (113  ±  18  bpm  vs  112  ±  16  bpm,  respectively;
 =  0.46).
No  signiﬁcant  difference  was  observed  between  the  walk-
ng  distances  after  the  control  and  RIPC  procedures  (204
RIPC  P
259]  215  [162—442]  0.22
3  —15.7  ±  7.8  0.93
38.8  ±  3.2  0.68
15.2  ±  0.7  0.25
14.2  ±  0.9  0.31
112  ±  16  0.46
105  ±  4  0.32
96  ±  5  0.28
 1.51  ±  0.06  <0.001
 3.63  ±  0.44  0.29
ard deviation.
om rest at the end of exercise; HR: heart rate; HRmax: maximal
tO2end: oxygen saturation at the end of exercise; STPD: standard
t the end of exercise; VO2end: oxygen consumption at the end of
Remote  ischaemic  preconditioning  in  intermittent  claudication  
Figure 2. Effect of remote ischaemic preconditioning (RIPC) on
maximal walking distance, expressed as the difference between
maximal walking distance measured after the control procedure and
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arms,  therefore  exposing  a  large  amount  of  tissue  volume  toafter RIPC. Values are expressed in metres (m). Each line represents
one patient.
[141—259]  m  vs  215  [162—442]  m,  respectively;  P  =  0.22)
(Fig.  2).  There  were  no  differences  observed  in  tissue
oxygenation  (DROPend  =  —15.7  ±  7.8  mmHg  after  RIPC  and
—15.6  ±  9.3  mmHg  after  control;  P  =  0.93).  Patients  with
the  control  procedure  ﬁrst  exhibited  a  slight  increase  in
walking  distance  between  the  ﬁrst  and  second  tests:  200
(115—283)  m  and  213  (152—483)  m,  respectively  (P  =  0.24).
Patients  with  RIPC  ﬁrst  exhibited  a  slight  decrease  in
walking  distance  between  the  ﬁrst  and  second  tests:  229
(136—907)  m  and  211  (121—730)  m,  respectively  (P  =  0.63).
As  expected,  blood  lactate  concentrations  before  exer-
cise  were  signiﬁcantly  higher  after  RIPC  than  those  recorded
after  the  control  procedure  (1.51  vs  1.16  mmol/L,  respec-
tively;  P  <  0.001),  although  no  signiﬁcant  difference  was
observed  between  the  groups  for  post-exercise  concentra-
tions.
Discussion
RIPC  is  known  to  protect  tissues  against  I/R  injury  that
occurs  in  several  clinical  settings  such  as  cardiac  surgery
with  cardiopulmonary  bypass  [10—12,23,24]  and  ST-segment
elevation  myocardial  infarction  [15,16].  However,  the  mech-
anism  through  which  RIPC  exerts  its  protection  is  still
unclear.  RIPC  is  believed  to  produce  protective  signals
that  are  conveyed  from  the  remote  tissue  to  the  tar-
get  organ  [7,25].  Several  mechanisms  may  be  involved,
including  blood-borne  factor  release  [26—28],  neuronal
t
r
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athway  activation  [29]  and  systemic  response  participa-
ion  [30]. These  protective  signals  may  activate  intracellular
urvival  signalling  pathways  in  the  target  organ  [25,31].
everal  studies  have  reported  the  involvement  of  endoge-
ous  factors  in  protective  mechanisms,  such  as  adenosine
32], endocannabinoids  [33], bradykinin  [34],  opioids  [35],
rythropoietin  [36],  microvesicles  [37],  apolipoprotein  A-I
38]  and  microRNA  [39]. The  actual  identity  of  circulating
umeral  factors  currently  remains,  however,  unknown.
Intermittent  claudication  is  a  condition  in  which  patients
ith  peripheral  artery  disease  experience  a  decline  in  qual-
ty  of  life  because  of  exercise  intolerance  related  to  limb
schaemia.  On  this  basis,  we  hypothesized  that  RIPC  could
mprove  exercise  capacity  in  patients  with  intermittent
laudication.  It  was  interesting  to  note  that  conducting  pre-
onditioning  procedures  on  both  legs  in  well-trained  cyclists
hrough  repeated  series  of  5-minute  ischaemia,  followed  by
-minute  reperfusion  before  an  incremental  bicycle  exercise
est  was  found  to  improve  maximal  oxygen  consumption  by
%  and  power  output  by  1.6%  [18]. Similarly,  four  cycles  of
-minute  arm  ischaemia  followed  by  5-minute  reperfusion
sing  a  blood-pressure  cuff  were  shown  to  improve  max-
mal  performance  in  highly  trained  swimmers  [17].  Some
tudies  have  suggested  that  RIPC  might  modify  skeletal  mus-
le  tolerance  to  tissue  hypoxia,  thereby  increasing  maximal
xercise  performance  [17].  Furthermore,  previous  stud-
es  have  demonstrated  the  potential  beneﬁcial  effects  of
schaemic  preconditioning  through  functional  changes  in
he  vasculature  and  adaptions  of  the  skeletal  muscles  [40].
schaemic  preconditioning  may  induce  the  opening  of  mito-
hondrial  adenosine  triphosphate  (ATP)-sensitive  potassium
hannels  and  uncoupling  phosphorylation  [41].  In  human
ubjects,  Loukogeorgakis  et  al.  demonstrated  that  RIPC,
hen  applied  in  repeated  cycles  of  5-minute  ischaemia  and
-minute  reperfusion  on  the  contralateral  arm  or  leg,  was
ffective  in  preventing  endothelial  I/R  injury,  with  the  pro-
ection  being  dependent  on  the  activation  of  ATP-sensitive
otassium  channels  [42].
In  a  recent  unblinded  study,  patients  with  intermittent
laudication  underwent  two  treadmill  tests  separated  by
 7-day  interval,  one  consisting  of  RIPC  (three  series  of
-minute  arm  ischaemia  and  5-minute  reperfusion  using  a
lood-pressure  cuff)  applied  90  minutes  before  the  test  and
ne  without  RIPC  [43]. RIPC  was  associated  with  an  increased
istance  to  pain  manifestation,  yet  proved  ineffective  on  the
otal  walking  distance.  In  the  PARADIS  study,  we  also  found
hat  RIPC  did  not  signiﬁcantly  alter  the  walking  distance.
he  distance  to  pain  manifestation  was  not  recorded,  as
e  instead  opted  to  collect  more  robust  variables  assessing
imb  ischaemia  during  exercise.  None  of  these  variables  was
ffected  by  the  use  of  RIPC.
It  is  as  yet  unclear  why  RIPC  did  not  improve  the  walk-
ng  distance  in  patients  with  intermittent  claudication.  We
ust  ﬁrst  determine  if  the  protection  trigger  was  optimal.
 comparison  of  the  different  remote  conditioning  meth-
ds  previously  suggested  that  a  threshold  stimulus  must  be
eached  to  fully  document  the  beneﬁcial  effects  [42,44].
n  the  PARADIS  study,  the  RIPC  protocol  involved  both  upperhe  preconditioning  stimulus.  Furthermore,  the  RIPC  algo-
ithm  applied  in  the  PARADIS  study,  namely  three  cycles  of
-minute  ischaemia  and  5-minute  reperfusion,  was  similar  to
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[17] Jean-St-Michel E, Manlhiot C, Li J, et al. Remote precondition-
ing improves maximal performance in highly trained athletes.78  
hat  reported  in  several  positive  trials  applying  it  in  the  sett-
ngs  of  cardiac  surgery  [12]  and  myocardial  infarction  [16].
iven  that  patients  with  intermittent  claudication  were  con-
tantly  exposed  to  sequences  of  I/R  in  the  lower  limbs,
hich  generates  repetitive  signals  of  ischaemic  precondi-
ioning,  it  is  fair  to  assume  that  a  maximal  activation  of  the
rotective  signalling  pathways  had  already  been  achieved,
eaning  that  RIPC  would  not  have  produced  additional  pro-
ection.  Nevertheless,  one  cannot  exclude  the  possibility
hat  an  associated  treatment  could  have  altered  the  RIPC-
nduced  protective  effect.  In  the  PARADIS  study,  70%  of
atients  were  treated  with  clopidogrel,  which  can  activate  a
onditioning-like  protection  independently  of  its  antithrom-
otic  effect  [45].  Even  if  no  link  has  yet  been  established
etween  RIPC  mechanisms  and  platelet  reactivity,  Batti-
aglia  et  al.  have  suggested  that  RIPC  may  induce  protection
gainst  an  exercise-related  increase  in  platelet  reactivity
n  patients  with  stable  coronary  artery  disease  [46]. Based
n  this  theory,  clopidogrel  treatment  could  have  inﬂuenced
his  response  in  the  PARADIS  study.  Similarly,  90%  of  patients
eceived  chronic  statin  treatment,  but  it  has  been  reported
hat  statins  may  interfere  with  the  protective  effects  of
schaemic  conditioning  [47].
tudy limitations
iven  that  the  feelings  induced  by  blood-pressure  cuff  inﬂa-
ion  to  200  mmHg  and  10  mmHg  are  clearly  different,  the
atients  were  consequently  not  completely  blinded  to  the
rocedure.  Nevertheless,  the  patients  were  not  told  which
f  the  procedures  could  have  a  beneﬁcial  effect.  In  addi-
ion,  we  only  tested  one  RIPC  protocol,  exploring  the  early
hase  of  conditioning.  It  is  as  yet  unknown  if  other  RIPC
equences  and  other  timings  would  have  induced  similar
egative  results.  Finally,  the  limited  sample  size  of  the  study
ay  have  underpowered  the  ability  of  the  study  to  detect
ny  change  after  RIPC.
onclusions
IPC  did  not  improve  walking  distance  or  any  variables  of
imb  ischaemia  in  patients  with  peripheral  artery  disease
nd  intermittent  claudication.
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